Xeris Biopharma Holdings (XERS) Share-based Compensation (2020 - 2026)

Xeris Biopharma Holdings has reported Share-based Compensation for 7 years, with the latest figure at $4.1 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 6.82% year-over-year to $4.1 million; the trailing twelve-month figure through Mar 2026 stood at $22.1 million (up 15.88% YoY), and the FY2025 full-year result was $22.4 million, up 21.8% from the prior year.
• Share-based Compensation for Q1 2026 stood at $4.1 million, down from $5.3 million in the prior quarter.
• The five-year high for Share-based Compensation was $7.6 million in Q3 2025, with the low at $2.5 million in Q3 2023.
• Historically, Share-based Compensation has averaged $4.0 million across 5 years, with a median of $3.6 million in 2024.
• Annual changes were most pronounced in 2023 — Share-based Compensation declined 22.33% — and 2024, when it surged 175.46%.
• Xeris Biopharma Holdings' Share-based Compensation stood at $2.8 million in 2022, then rose by 0.04% to $2.8 million in 2023, then climbed by 29.92% to $3.6 million in 2024, then soared by 46.65% to $5.3 million in 2025, then dropped by 21.47% to $4.1 million in 2026.
• The last three Share-based Compensation figures came in at $4.1 million (Q1 2026), $5.3 million (Q4 2025), and $7.6 million (Q3 2025), per Business Quant data.